Sign inJoin waitlistJoin the waitlist

Yinghong Wang

Research Deputy Division Head · University of Texas M D Anderson Cancer Center

Credentials: · · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Gastroenterology
Cleveland Clinic Foundation
2008–2011
Internal Medicine
Albany Med Health System
2005–2008
China Medical University 2nd Affiliated Hospital
1996–1997
Doctor of Medicine
1993–1997

Research

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Nature Immunology · 2005 · 3,389 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 2,915 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Journal of Clinical Oncology · 2021 · 1,863 citations

HA
Hamzah Abu-Sbeih
48 papers · 40 as a resident
Malek Shatila
45 papers
Mehmet Altan
22 papers
JT
John Thompson
21 papers
FA
Faisal Ali
17 papers · 17 as a resident
Gottumukkala Raju
15 papers
Abdul Naqash
14 papers · 5 as a fellow
AS
Anwaar Saeed
14 papers
Bryan Schneider
14 papers
Pablo Okuysen
14 papers
Ahmed Kaseb
12 papers
David Richards
12 papers

Clinical trials

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2027
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2021–2026
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2021–2027
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2020–2027